Omrix Biopharmaceuticals, Inc. (OMRI) is a publicly traded company in the Unknown sector. Across all available filings, 19 corporate insiders have executed 77 transactions totaling $36.1M, demonstrating a bearish sentiment with -$33.1M in net insider flow. The most recent transaction on Nov 23, 2008 involved a transaction of 40,000 shares valued at $0.
No significant insider buying has been recorded for OMRI in the recent period.
No significant insider selling has been recorded for OMRI in the recent period.
Based on recent SEC filings, insider sentiment for OMRI is bearish with an Insider Alignment Score of 4/100 and a net flow of -$33.1M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Omrix Biopharmaceuticals, Inc. (OMRI) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 19 insiders are actively trading OMRI stock, having executed 77 transactions in the past 90 days. The most active insider is Robert Taub (Executive), who has made 6 transactions totaling $24.6M.
Get notified when executives and directors at OMRI file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Nov 23, 2008 | Taub Robert | Executive | Award | 40,000 | $N/A | $0 | |
| Oct 10, 2008 | Mashiach Nissim | Executive | Award | 20,000 | $N/A | $0 | |
| Sep 4, 2008 | Ellberger Larry | Executive | Award | 3,000 | $N/A | $0 | |
| Sep 4, 2008 | Horowitz Bernard | Executive | Award | 2,000 | $N/A | $0 | |
| Sep 4, 2008 | Rakin Kevin | Executive | Award | 2,000 | $N/A | $0 | |
| Sep 4, 2008 | Romagnoli Philippe | Executive | Award | 2,000 | $N/A | $0 | |
| Sep 4, 2008 | Steven St Peter | Executive | Award | 2,000 | $N/A | $0 | |
| May 15, 2008 | W. Mcnamara Pamela | Executive | Award | 2,000 | $N/A | $0 | |
| Mar 31, 2008 | Mashiach Nissim | Executive | Purchase | 2,000 | $14.50 | $29.0K | |
| Mar 26, 2008 | Romagnoli Philippe | Executive | Purchase | 7,800 | $13.59 | $106.0K | |
| Mar 26, 2008 | Rakin Kevin | Executive | Purchase | 1,500 | $13.65 | $20.5K | |
| Mar 26, 2008 | Rakin Kevin | Executive | Purchase | 500 | $13.64 | $6.8K | |
| Mar 20, 2008 | Taub Robert | Executive | Purchase | 26,400 | $12.10 | $319.4K | |
| Mar 20, 2008 | Romagnoli Philippe | Executive | Purchase | 8,250 | $12.02 | $99.2K | |
| Mar 19, 2008 | Taub Robert | Executive | Purchase | 53,600 | $12.31 | $659.8K | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 17 | $34.6M | 91.4% |
Exercise(M) | 12 | $1.8M | 4.7% |
Purchase(P) | 12 | $1.5M | 4.0% |
Award(A) | 20 | $0 | 0.0% |
Gift(G) | 2 | $0 | 0.0% |
Other(J) | 14 | $0 | 0.0% |
Insider selling pressure at Omrix Biopharmaceuticals, Inc. has increased, with 19 insiders executing 77 transactions across all time. Total sales of $34.6M significantly outpace purchases of $1.5M, resulting in a net outflow of $33.1M. This selling activity appears largely discretionary, which may warrant closer attention from investors.